"We at Galderma are delighted to bring Restylane, Perlane, Emervel, and Dysport home in the U.S. and Canada as is the case in dozens of countries around the world. Adding Sculptra to our global portfolio allows us to bring additional indications to our broad range of medical solutions for people with skin needs," said Humberto C. Antunes, CEO and president of Galderma worldwide. "Our science-based approach to fillers and muscle relaxants takes our solutions beyond the aesthetic level to an integral part of holistic medicine, where maintaining, preserving and restoring the health of the skin is as important and as relevant as treating or correcting conditions. With Restylane, Perlane, and Dysport, as well as the innovations to come, we complement our line of prescription and self-medication products to give physicians an arsenal of effective solutions," added Antunes.
Two of Galderma's most recent innovations in the field, Emervel Classic and Emervel Deep, have been submitted for approval by the FDA and Health Canada and are currently under review.
"The US and Canada represent more than 50 percent of the fast growing global medical aesthetics markets," said Stuart Raetzman, VP of Galderma for North America. "Demographics, social and cultural drivers, as well as an improving economy, make this an ideal time for Galderma to expand its geographic footprint in aesthetic and corrective medicine to the United States and Canada. At Galderma, people come first. We are thrilled to take on board the experienced teams from Valeant Aesthetics and, more than ever, our intent is to preserve the quality of the long-lasting relationships built with doctors. We look forward to partnering with healthcare providers in the growth and expansion of aesthetic and corrective medicine in North America and advancing the care and treatment of patients."